As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing ...

Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...

Thirty-two patients with locally advanced bowel cancer received a short course of the immunotherapy drug pembrolizumab before ...

Kelun-Biotech, listed under stock code 6990.HK, announced its Phase III OptiTROP-Lung06 trial of sac-TMT combined with ...

Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside the immunotherapy drug ...

LUND, SE / ACCESS Newswire / July 17, 2026 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the ...

Optimized immunotherapy workflow saves drug costs and frees infusion chair time at Charles S. Kettles VA Medical Center over 12 months.

Bangladesh’s pharmaceutical industry’s next phase of growth will depend on sustained investment in research and development, ...

ANKTIVA drives NMIBC growth, pipeline upside, and a 40% pullback entry. Click here to read more about IBRX.

Recently validated markers have helped improve treatment but more are needed ...

Persistent hyponatremia despite treatment prompts further evaluation, revealing isolated aldosterone deficiency despite normal adrenal function and leading to effective therapy.

FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein C-III-directed antisense oligonucleotide ...